MaxCyte (MXCT) Earnings Date & Reports

Key Takeaways

• Total revenue reached $10.2 million in the third quarter of 2026, up 49% from $6.8 million a year earlier.
• Core revenue grew 27% to $8.2 million, while Strategic Platform License (SPL) program-related revenue contributed roughly $2.0 million.
• Net loss narrowed to $4.8 million, or $0.05 per share, from $12.4 million, or $0.12 per share, in the prior-year period.
• Management raised full-year 2026 revenue guidance to at least $34.5 million and announced a definitive agreement to acquire Akron Bio.
• For more details on MaxCyte's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages for a fuller picture of the stock.
• For broader market ideas, explore Trending AI Robots to see AI-driven trading strategies across multiple sectors.

Earnings Context and Why It Matters

MaxCyte, a cell-engineering company that supplies enabling platform technologies for cell and gene therapy developers, entered 2026 focused on returning to growth after a challenging 2025 in which annual revenue declined about 15%. Its third-quarter report is a key test of that turnaround. The company generates revenue through instrument sales, processing assemblies, and Strategic Platform License (SPL) agreements, which tie MaxCyte's economics to the clinical and commercial progress of its partners. Because SPL milestones and royalties are variable, investors watch both core revenue and SPL activity closely. This quarter also carried extra weight because MaxCyte used the release to announce a transformative acquisition, making the results a signal of both near-term momentum and long-term strategic direction.

Reported Results

For the three months ended September 30, 2026, MaxCyte reported total revenue of $10.2 million, a 49% increase from $6.8 million in the third quarter of 2025. Core revenue rose 27% to $8.2 million, driven in part by accelerated instrument purchases from a large customer that management had originally expected in the fourth quarter. SPL program-related revenue totaled about $2.0 million, including milestone and royalty revenue.

Net loss narrowed to $4.8 million, or $0.05 per share, from $12.4 million, or $0.12 per share, a year earlier, reflecting both higher revenue and continued cost discipline. Gross profit was $8.5 million, up from $5.2 million. The results came in ahead of Wall Street expectations, with the reported loss per share of $0.05 comparing favorably to a consensus estimate of a $0.08 loss.

Management also raised full-year 2026 revenue guidance to at least $34.5 million, up from the approximately $34 million guided in October and from a prior range of $30 million to $32 million. For the nine months ended September 30, 2026, revenue was $27.1 million, up from $25.7 million in the same period of 2025.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For those following MaxCyte or the broader cell and gene therapy space, the screener offers a practical way to surface comparable setups and emerging opportunities.

Market Reaction and Investor Sentiment

Heading into the report, MaxCyte shares traded around $1.30, with analyst consensus at a "Strong Buy" rating and a 12-month average price target well above the market price. The company had already signaled a strong quarter in mid-October, when it disclosed preliminary third-quarter revenue and raised guidance, giving investors an early read on momentum. The full results reinforced that message, with revenue above consensus and a narrower loss than expected. The announcement of the Akron Bio acquisition added a strategic catalyst that could reshape how the market values the business. Still, MaxCyte remains unprofitable and cash-flow negative, so sentiment will likely hinge on execution of the acquisition and the path toward profitability rather than a single quarter's beat.

Forward Outlook and Key Factors to Monitor

The most significant development for investors to track is the planned acquisition of Akron Bio, which management described as a move to broaden MaxCyte into a wider cell therapy manufacturing partner. Akron Bio is expected to generate roughly $28 million in revenue in 2026 and $7 million to $8 million in EBITDA (earnings before interest, taxes, depreciation, and amortization), and is already cash-flow positive. On a pro forma basis, the combined company is expected to generate more than $60 million in 2026 revenue, nearly doubling MaxCyte's standalone revenue base.

Investors should monitor the closing and integration of that transaction, including the associated costs, debt obligations, and potential shareholder dilution. Another key factor is the trajectory of core revenue growth, which management now expects to be roughly 15% year over year in the second half of 2026.

Finally, watch SPL activity and the progress of partner clinical programs, including two pivotal trials that management said could support potential approvals as early as next year. Milestones and royalties tied to those programs can create lumpy but meaningful revenue, making clinical and regulatory updates an important catalyst for the stock.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations